Virobay Facts

2014 – Virobay completes $8 million Series B preferred stock financing more

2014 – Virobay announces the appointment of James Welch as Chief Financial Officer more

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

more

Welcome to Virobay, developers of protease inhibitors

We are a clinical-stage biopharmaceutical company utilizing our cysteine cathepsin platform for the development and commercialization of novel drugs. We believe cysteine cathepsins are critically important enzymes in the biology of many diseases. By inhibiting these enzymes, we believe we can develop safer and more effective therapies for these diseases.

Our current programs are focused on addressing significant unmet medical needs for the treatment of neuropathic pain, autoimmune diseases and fibrosis.

Our Pipeline

Virobay Pipeline Table
 
Research
 
Phase 0
(Clinical Candidate)
 
Phase 1
 
Phase 2
VBY-891
Psoriasis - LEO Pharma     X  
VBY-036
Pain     X  
Crohn's Disease     X  
VBY-376
Fibrosis/NASH     X  
VBY-825
Fibrosis/PBC   X    
Multiple Candidates
Cancer, Alzheimer's X